Brim Biotechnology, Inc. · TWSE:6885
Brim Biotechnology — Investor Presentation (May 2022)
14 slides from Brim Biotechnology's investor presentation, May 12, 2022
Slide 1: BRIM Biotechnology
BRIM Biotechnology May 12, 2022 Beyond Research and Innovative Medicines DISCLAIMER: This document contains information that is privileged. This information is intended only for the use of the individuals and entities to whom it is addressed. Any further disclosures are prohibited and possibly a vio
Slide 2: Founders
2 Founders Haishan Jang, PhD Frank Lee, PhD Chief Executive Officer & Chief Strategy Officer & BRIM Taiwan Chairman BRIM Cayman Chairman 30+ years experience 41+ years experience • Previously a member of Senior Management at Centocor • Previously Vice President of DMPK at Takeda • Former Manager at
Slide 3: Our approach
3 Our approach Maximize ROI through Reduced IND enabling Good budget control of early exit at clinical proof time (1.5-3 years from both R&D and fixed cost of concept (PoC) lead ID to IND submission) Incubation Academia, Projects Small Value Biotech Adding Value Creation: Out-license Clinical Lead C
Slide 4: Global DES population: 915m
Global DES population: 915m severe DES: ~90m DISCLAIMER: This document contains information that is privileged. This information is intended only for the use of the individuals and entities to whom it is addressed. Any further disclosures are prohibited and possibly a violation of law and regulation
Slide 5: DES Market: 5.21 Billion USD in 2021
5 DES Market 2021 GLOBAL MARKET SIZE: 5.21 Billion USD1 2027 GLOBAL MARKET SIZE PROJECTION: ~7 Billion USD1 CAGR（2019-2027) 5.12%1 2019 2027 References: 1. https://www.mordorintelligence.com/industry-reports/dry-eye-disease-market DISCLAIMER: This document contains information that is privileged. Th
Slide 6: Beyond the Current Standard of Care
Beyond the Current Standard of Care 6 BRM421 Unique MoA Stimulate proliferation and differentiation of corneal limbal stem cells to speed up cornea repair process Promote proliferation and differentiation of goblet cells to improve tear quality Corneal Wound Self- renewal Limbal stem cell (LSC) Asym
Slide 7: DES competitors on market
DES competitors on market 7 COMPANY/D DRUG ONSET MOA / API STATUS FREQUENCY SIDE EFFECT PATENT COMMENTARY RUGS TYPE (WEEKS) BRIM/ stem cell regeneration/ Instillation site Visual Peptide US Phase 2 2 3x daily 2041 BRM421 PEDF-derived peptide reaction (37%) Improvement NOVARTIS/ Small Anti-inflammati
Slide 8: BRIM has Licensed BRM421 CN Rights to China Grand Pharm
8 BRIM has Licensed BRM421 CN Rights to China Grand Pharm China Grand Pharm (CGP), HK: 0512 China the 5th largest Over Hong Kong healthcare group in China USD 85M Macau total deal size regional rights DISCLAIMER: This document contains information that is privileged. This information is intended onl
Slide 9: BRM421 efficacy in mouse DES model
9 BRM421 efficacy in mouse DES model 1% CMC Vehicle Mice housed at CEC for 14 days Normal Restasis 0.1% Dex Vehicle + BRM421 without topical treatment Day 1 Drug dosing 3x a day for seven (Dry eye induced days in a normal environment at CEC for 14 days) Topical BRM421 displays therapeutic effect in
Slide 10: PDSP 29mer can effectively regenerate healthy limbus (Rabbit Model)
PDSP 29mer can effectively regenerate healthy limbus after 10 extensive limbal layer removal (Rabbit Model) DISCLAIMER: This document contains information that is privileged. This information is intended only for the use of the individuals and entities to whom it is addressed. Any further disclosure
Slide 11: First-in-Human Study Showed a Positive Trend
11 First-in-Human Study Showed a Positive Trend: Effective in Treating DES Sign Symptom Ad Hoc Analysis: Ad Hoc Analysis: Mean change from Mean change from Baseline in sign from Baseline in Dryness from fluorescein total corneal Ora Calibra® Ocular staining scores in Discomfort & 4-Symptom moderate
Slide 12: BRM421 is ready for Phase III study
12 BRM421 is ready for Phase III study Phase II/III Phase III Enrollment Moderate-to-severe Moderate-to-severe * same design Criteria Duration 14 days 14 days * same design Endpoint: Fluorescein total corneal staining Fluorescein total corneal staining * same design Sign at Visit 4 (Day 15) at Visit
Slide 13: Development milestones
13 Development milestones PRODUCT PLATFORM INDICATION 2020 2021 2022 2023 2024 2025 2026 PDSP (Peptide) Dry Eye Syndrome BRM421 SIH Phase 2 CMC EOP2 Phase Phase 33 NDA Neurotrophic Keratitis PDSP (Peptide) ODD BRM424 (Rare Disease) Phase 2 Pivotal Study /IND PDSP (Peptide) Osteoarthritis Discovery N
Slide 14: Thank you
Thank you Contact Person: Yi-Chun Maria Chen VP of Business Development yichun.chen@brimbiotech.com Beyond Research and Innovative Medicines DISCLAIMER: This document contains information that is privileged. This information is intended only for the use of the individuals and entities to whom it is
BRIM Biotechnology — Investor Presentation (May 2022) on 6ix